Evidence map›Paper›PMID 42277187›Full record

ArticlePediatric research2026

Type I interferon signature does not correlate with disease activity in Blau syndrome.

Benjamin Fournier, Héloïse Reumaux, Isabelle Melki, Florence Uettwiller, Mathilde Labouret, Cécile Dumaine, Marie-Laure Le Lez, Pierre Labelette, Gillian I Rice, Luis Seabra and 5 more

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Benjamin FournierPediatric Immuno-hematology and Rheumatology department, Hôpital Necker-Enfants Malades, Reference Centre for Inflammatory Rheumatism, Autoimmune Diseases and Systemic Interferonopathies in Children (RAISE), F-CRIN CRI-IMIDIATE network, AP-HP. Centre Université Paris Cité, F-75015 Paris, France. benjamin.fournier@aphp.fr.
Héloïse ReumauxPediatric Rheumatology Department, Centre de Compétence des Rhumatismes inflammatoires, maladies Auto-immunes et Interféronopathies Systémiques de l'Enfant RAISE, Jeanne de Flandre University Hospital, Lille, France.
Isabelle MelkiGeneral Pediatric Department, Hôpital Armand-Trousseau, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne Université, Paris, France.
Florence UettwillerDepartment of Pediatrics, Centre de Référence des Rhumatismes inflammatoires, maladies Auto-immunes et Interféronopathies Systémiques de l'Enfant RAISE, Centre Hospitalier Régional Universitaire (CHRU) de Tours, Tours, France.
Mathilde LabouretDepartment of Pediatric Infectious Diseases and Internal Medicine, Robert-Debré University Hospital, APHP, Centre de Référence National pour les Rhumatismes et les Maladies Inflammatoires et Systémiques Rares de l'Enfant, AP-HP, Paris, France.
Cécile DumaineDepartment of Pediatric Infectious Diseases and Internal Medicine, Robert-Debré University Hospital, APHP, Centre de Référence National pour les Rhumatismes et les Maladies Inflammatoires et Systémiques Rares de l'Enfant, AP-HP, Paris, France.
Marie-Laure Le LezDepartment of Ophthalmology, Centre Hospitalier Régional Universitaire (CHRU) de Tours, Tours, France.
Pierre LabeletteDepartment of Ophthalmology, Centre Hospitalier Régional Universitaire (CHRU) de Lille, Lille, France.
Gillian I RiceDivision of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
Luis SeabraLaboratory of Neurogenetics and Neuroinflammation, INSERM UMR 1163, Université Paris Cité, Imagine Institute, F-75015 Paris, France.
Pierre Quartier-Dit-MairePediatric Immuno-hematology and Rheumatology department, Hôpital Necker-Enfants Malades, Reference Centre for Inflammatory Rheumatism, Autoimmune Diseases and Systemic Interferonopathies in Children (RAISE), F-CRIN CRI-IMIDIATE network, AP-HP. Centre Université Paris Cité, F-75015 Paris, France.
Audrey LaurentPediatric Rheumatology, Centre de Référence des Rhumatismes inflammatoires, maladies Auto-immunes et Interféronopathies Systémiques de l'Enfant RAISE, HFME, Hospices Civils de Lyon, Lyon, France.
Marie-Louise FrémondPediatric Immuno-hematology and Rheumatology department, Hôpital Necker-Enfants Malades, Reference Centre for Inflammatory Rheumatism, Autoimmune Diseases and Systemic Interferonopathies in Children (RAISE), F-CRIN CRI-IMIDIATE network, AP-HP. Centre Université Paris Cité, F-75015 Paris, France.
Brigitte Bader-MeunierPediatric Immuno-hematology and Rheumatology department, Hôpital Necker-Enfants Malades, Reference Centre for Inflammatory Rheumatism, Autoimmune Diseases and Systemic Interferonopathies in Children (RAISE), F-CRIN CRI-IMIDIATE network, AP-HP. Centre Université Paris Cité, F-75015 Paris, France.
Carine WoutersDivision of Pediatric Rheumatology, Department of Pediatrics, University Hospitals Leuven, Leuven, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Blau syndrome is a rare autoinflammatory disorder caused by NOD2 mutations, characterized by granulomatous arthritis, uveitis, and dermatitis. While type I interferon signatures are biomarkers in several autoinflammatory diseases, their role in Blau syndrome remains unclear. We assessed the interferon score in 11 patients with Blau syndrome and correlated it with disease activity. Our results demonstrate that type I interferon signatures were detected in only a minority of patients and showed no significant correlation with clinical disease activity, inflammatory markers, or treatment response. These findings suggest that type I interferon signatures are not useful biomarkers for disease monitoring in Blau syndrome, highlighting the need to identify alternative biomarkers reflecting NOD2-mediated inflammatory pathways.

Identifiers

PMID42277187

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.